ALDA Pharmaceuticals Corp.

ALDA Pharmaceuticals Corp.

April 12, 2007 19:03 ET

ALDA Grants Incentive Stock Options

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 12, 2007) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has granted incentive stock options to certain directors to purchase an aggregate of 500,000 common shares at an exercise price of $0.11 and a term of two years, expiring on August 12, 2009. The options and shares issuable upon exercise, if any, will be subject to a four-month hold period from the date of grant in accordance with TSX Venture Exchange policy. The grant was pursuant to the Company's Rolling Stock Option Plan, which was re-affirmed by the shareholders of the Company on December 15, 2006 and subsequently accepted by the Exchange. The total number of options outstanding after this grant will be 2,130,000.

About ALDA Pharmaceuticals Corp.

ALDA's patent-pending T36® treatments for infectious diseases contain active ingredients in very low concentrations that disrupt the physical structure of all infectious organisms rather than interfering with their metabolic pathways. The competitive advantage of this approach is the ability to kill all infectious organisms while preventing microbial resistance, side effects or toxicity.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

ALDA Pharmaceuticals Corp.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information